Morphic Medical

Executive Summary

Morphic Medical is a privately held medical device company developing RESET® therapy, a novel, endoscopically delivered device aimed at treating type 2 diabetes and obesity. The therapy targets underlying metabolic mechanisms to bridge the gap between pharmaceutical interventions and bariatric surgery. Founded in 2018 and headquartered in Boston, Massachusetts, the company focuses on providing a minimally invasive solution that could offer durable weight loss and glycemic control with reduced side effects compared to surgery. Morphic Medical operates in the medical devices and gastroenterology sectors, positioning itself as an innovator in the rapidly growing metabolic disease market. The company is currently advancing its RESET® therapy through clinical development, with key milestones anticipated in the near term. As a private entity, Morphic Medical's progress is less transparent, but the unmet need in obesity and diabetes care, combined with its differentiated approach, supports significant upside potential. Success in clinical trials and regulatory pathways could drive adoption and partnerships. However, given the early stage and competitive landscape, execution risk remains moderate. The company's conviction score reflects the promise of its technology balanced against developmental uncertainties and the need for clinical validation.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical trial for RESET therapy70% success
• Q2 2026FDA breakthrough device designation or IDE approval60% success
• Q3 2026Strategic partnership with a major obesity/diabetes company50% success